Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan-Reference-Cited by-同舟云学术

Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan

Published:2023 Issue:4 Volume:12 Page:319
ISSN:2287-3651
Container-title:Clinical and Experimental Vaccine Research
language:en
Short-container-title:Clin Exp Vaccine Res

Author:

Marumo Yoshiaki¹²^ORCID,Yoshida Takashi¹^ORCID,Furukawa Yuki¹^ORCID,Ina Kenji¹³^ORCID,Kamiya Ayumi¹^ORCID,Kataoka Takae¹^ORCID,Kayukawa Satoshi¹^ORCID

Affiliation:

1. Department of Clinical Oncology, Nagoya Memorial Hospital, Nagoya, Japan.

2. Department of Hematology and Oncology, Nagoya City University, Nagoya, Japan.

3. Department of Geriatric Medicine, Shinseikai Daiichi Hospital, Nagoya, Japan.

Publisher

XMLink

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pharmacology,Immunology and Allergy

Link

https://ecevr.org/pdf/10.7774/cevr.2023.12.4.319

Reference21 articles.

1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19: 11 March 2020 [Internet]. Geneva. World Health Organization. 2020. cited 2023 May 15. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

2. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

3. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

5. Pharmaceutical and Medical Devices Agency. Special approval for emergency on first COVID-19 vaccine in Japan [Internet]. Tokyo. Pharmaceutical and Medical Devices Agency. 2021. cited 2022 Dec 5. https://www.pmda.go.jp/english/about-pmda/0003.pdf